Beqalzi

News

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.

News

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.